#5-42E. Objective Monitoring and Targeted Therapies in Eosinophilic Esophagitis (JACI, 2026)

How do you ensure you are truly preventing long-term esophageal remodeling in your patients with eosinophilic esophagitis (EoE) when clinical symptoms do not always match underlying mucosal damage? This comprehensive review paper in JACI synthesizes emerging insights into the complex pathophysiology of EoE, detailing how environmental allergens trigger epithelial barrier breakdown, sensory nerve hypersensitivity, and inflammatory cell recruitment. The authors outline a multifaceted treatment strategy, including food elimination diets, acid-reducing medications, and newly FDA-approved therapies such as dupilumab and budesonide oral suspension. The pivotal clinical takeaway is the imperative need to monitor objective histological, endoscopic, and molecular transcriptomic parameters over mere symptomatic control to avoid stricture formation. However, because this is a narrative review, clinicians must critically evaluate that the summarized data draws from heterogeneous trials rather than a single standardized meta-analysis. Ultimately, this work equips physicians with a modern, high-yield therapeutic framework, advocating for strict, multi-dimensional disease monitoring to optimize individualized clinical decision-making and prevent progressive fibrotic complications in daily practice.

Citation: Simin Zhang, Marc E. Rothenberg, et al. Emerging insights into the presentation, pathophysiology, and management of eosinophilic esophagitis. The Journal of Allergy and Clinical Immunology. 2026. DOI: 10.1016/j.jaci.2026.04.026

URL: https://doi.org/10.1016/j.jaci.2026.04.026

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.